Pharma BD Deal Intelligence
Jounce Therapeutics announces update on strategic collaboration with Celgene Corporation restructuring the 2016 deal to focus on JTX-8064 macrophage-targeting…
Celgene scraps $2.6B deal and licenses Jounce antibody JTX-8064 in restructured cancer collaboration returning vopratelimab rights to Jounce Therapeutics.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Celgene licensed Jounce Therapeutics' immuno-oncology pipeline including JTX-2011 ICOS agonist antibody, paying $261M upfront with up to $2.48B in milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Jounce Therapeutics Inc. (this deal) | 2016 | $2.7B | 29 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2016 deals · Celgene Corporation deals · Oncology deals